Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > If this doesn't infuriate you

<< Previous

Bullboard Posts

Next >>

Comment by HarveyTwofaceon Jun 04, 2021 10:39am

125 Views

Post# 33329342

RE:RE:RE:If this doesn't infuriate you

It could be depressing if you put all of your eggs in the same basket. Never do that, always make sure you have funds or other shares you can sell with a profit so you can buy more shares from "the impatient". Best regards, Patient guy

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario